ABSTRACT: The crystal structure of the title compound, C(16)H(20)BrNO(3), contains three chiral centers in the configuration 1R,2S,6R. The cyclo-hexane ring is in a chair conformation. In the crystal, mol-ecules are linked by weak C-H?O inter-actions, forming chains along the a-axis direction.
Project description:The crystal structure of the title compoud, C(17)H(20)BrNO(3), contains three chiral centers, which all exhibit an S configuration. The C=C double bond has an E conformation. The cyclo-hexane ring is in a chair conformation. In the crystal, mol-ecules are linked by weak N-O?Br inter-actions [O?Br = 3.136?(4)?Å].
Project description:In the title compound, C(38)H(29)N(7)O(12), the five-membered ring adopts an envelope conformation in which the 'flap' is cis to the cyclo-propane group. This conformation is similar to those of other bicyclo-[3.1.0]hexane analogues for which crystal structures have been reported. The absolute configuration of the stereogenic centers on the cyclo-pentane ring, as determined by comparison with the known configurations of the stereogenic centers in the (2S)-2-acet-oxy-2-phenyl-acet-oxy groups, is 1(R), 2(R), 3(R), 4(R) and 5(S). An intramolecular N-H?O hydrogen bond is present.
Project description:Reductive cyclization of 1,3,5-triphenyl- and 3-(2-meth-oxy-phen-yl)-1,5-di-phenyl-pentane-1,5-diones by zinc in acetic acid medium leads to the formation of 1,2,4-tri-phenyl-cyclo-pentane-1,2-diol [1,2,4-Ph3C5H5-1,2-(OH)2, C23H22O2, (I)] and 4-(2-meth-oxy-phen-yl)-1,2-di-phenyl-cyclo-pentane-1,2-diol [4-(2-MeOC6H4)-1,2-Ph2C5H5-1,2-(OH)2, C24H24O3, (II)]. Their single crystals have been obtained by crystallization from a THF/hexane solvent mixture. Diols (I) and (II) crystallize in ortho-rhom-bic (Pbca) and triclinic (P ) space groups, respectively, at 150 K. Their asymmetric units comprise one [in the case of (I)] and three [in the case of (II)] crystallographically independent mol-ecules of the achiral (1R,2S,4r)-diol isomer. Each hydroxyl group is involved in one intra-molecular and one inter-molecular O-H⋯O hydrogen bond, forming one-dimensional chains. Compounds (I) and (II) have been used successfully as precatalyst activators for the ring-opening polymerization of ∊-caprolactone.
Project description:The title compound, C(15)H(16)BrNO, obtained from a two-step reaction, was prepared for use in transition metal chemistry as a phenolic ligand with bulky substituents. Inter-molecular N-H?O and O-H?N hydrogen bonds are present in the crystal structure.
Project description:The crystal structure of the title compound, C(12)H(17)BrNO(+)·Cl(-), is stabilized by N-H?Cl and C-H?O hydrogen bonds, forming a three-dimensional network. The inter-actions framework is completed by C-H?? contacts between a methyl-ene group and the benzene ring of a symmetry-related mol-ecule.
Project description:The title compound, C22H25NO5, was prepared by CAN [cerium(IV) ammonium nitrate] oxidation of the corresponding ?-lactam. The dihedral angle between the benzene rings is 13.3?(4)° and the C-N-C(=O)-C torsion angle is 176.1?(6)°. In the crystal, amide-C(4) N-H?O and reinforcing C-H?O hydrogen bonds link the mol-ecules into infinite  chains. Further C-H?O hydrogen bonds cross-link the chains in the c-axis direction.
Project description:In the crystal structure of the title compound, C(16)H(18)BrNO(3), the two stereogenic centres both have an S configuration. The cyclo-hexyl ring adopts a chair conformation. In the crystal, mol-ecules are linked by weak N-O?Br contacts [O?Br = 3.289?(4)?Å].
Project description:The title compound, C(5)H(8)ClNO(3), was prepared by the nucleophilic substitution reaction of (2S)-2-chloro-propanoyl chloride with glycine. The acetate group forms a dihedral angle of 84.6?(1)° with the mean plane of the C-NH-C=O fragment. In the crystal, the molecules are linked by N-H?O and O-H?O hydrogen bonds, generating a three-dimensional network, which consolidates the crystal packing.
Project description:The distribution, clearance, and bioavailability of (2S,6S)-hydroxynorketamine has been studied in the Wistar rat. The plasma and brain tissue concentrations over time of (2S,6S)-hydroxynorketamine were determined after intravenous (20 mg/kg) and oral (20 mg/kg) administration of (2S,6S)-hydroxynorketamine (n = 3). After intravenous administration, the pharmacokinetic parameters were estimated using noncompartmental analysis and the half-life of drug elimination during the terminal phase (t 1/2) was 8.0 ± 4.0 h and the apparent volume of distribution (V d) was 7352 ± 736 mL/kg, clearance (Cl) was 704 ± 139 mL/h per kg, and the bioavailability was 46.3%. Significant concentrations of (2S,6S)-hydroxynorketamine were measured in brain tissues at 10 min after intravenous administration, ?30 ?g/mL per g tissue which decreased to 6 ?g/mL per g tissue at 60 min. The plasma and brain concentrations of (2S,6S)-hydroxynorketamine were also determined after the intravenous administration of (S)-ketamine, where significant plasma and brain tissue concentrations of (2S,6S)-hydroxynorketamine were observed 10 min after administration. The (S)-ketamine metabolites (S)-norketamine, (S)-dehydronorketamine, (2S,6R)-hydroxynorketamine, (2S,5S)-hydroxynorketamine and (2S,4S)-hydroxynorketamine were also detected in both plasma and brain tissue. The enantioselectivity of the conversion of (S)-ketamine and (R)-ketamine to the respective (2,6)-hydroxynorketamine metabolites was also investigated over the first 60 min after intravenous administration. (S)-Ketamine produced significantly greater plasma and brain tissue concentrations of (2S,6S)-hydroxynorketamine relative to the (2R,6R)-hydroxynorketamine observed after the administration of (R)-ketamine. However, the relative brain tissue: plasma concentrations of the enantiomeric (2,6)-hydroxynorketamine metabolites were not significantly different indicating that the penetration of the metabolite is not enantioselective.